AN2 Therapeutics, Inc. (ANTX) Tops Q4 EPS by 2c

AN2 Therapeutics, Inc. (NASDAQ: ANTX) reported Q4 EPS of ($0.25), $0.02 better than the analyst estimate of ($0.27).

For earnings history and earnings-related data on AN2 Therapeutics, Inc. (ANTX) click here.

You May Also Be Interested In

• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• Kotak Upgrades Narayana Hrudayalaya Ltd (NARH:IN) to Buy (1)
• ICICI Securities Resumes Dalmia Bharat Ltd (DALBHARA:IN) at Add (2)